During the past decade, CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 4 clinical trials were completed, i.e. on average, 22.2% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 2 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique" #1 sponsor was "French Innovative Leukemia Organisation" with 10 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Groupe Francophone des Myelodysplasies" with 3 trials sponsored, "Astellas Pharma Inc" with 2 trials sponsored and "University Hospital, Bordeaux" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique" #1 collaborator was "AbbVie" with 2 trials as a collaborator, "Acute Leukemia French Association" with 2 trials as a collaborator, "Janssen-Cilag Ltd." with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator and "AstraZeneca" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique" are "Acute Myeloid Leukemia" (7 trials), "Myelodysplastic Syndromes" (4 trials), "Multiple Myeloma" (3 trials), "Lymphoma, Follicular" (2 trials) and "Acute Lymphoblastic Leukemia" (1 trials). Many other conditions were trialed in "CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique" in a lesser frequency.

Most popular intervention types in "CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique" are "Drug" (23 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (2 trials), "FK463" (2 trials), "Lenalidomide" (2 trials), "AG-120" (1 trials) and "AG-221" (1 trials). Other intervention names were less common.

The vast majority of trials in "CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique" are 25 trials for "All" genders.

Currently, there are NaN active trials in "CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique". undefined are not yet recruiting, 8 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique, 5 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".